Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049412 · ClinicalTrials.gov registry record · Phase 2
A Study for Patients With Type 1 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT01049412 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 138 participants.
The verdict
NCT01049412, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
Comparison of blood glucose levels in patients with Type 1 diabetes when they take a new basal insulin analog and when they take insulin glargine
Interventions
- DRUG Insulin glargine
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049412
The ClinicalTrials.gov registry entry for NCT01049412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine is the first listed.
NCT01049412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01049412 about?
NCT01049412 is a clinical study titled "A Study for Patients With Type 1 Diabetes". Comparison of blood glucose levels in patients with Type 1 diabetes when they take a new basal insulin analog and when they take insulin glargine
What is the current status of trial NCT01049412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01049412?
The interventions under investigation include: Insulin glargine (DRUG), LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01049412?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.